GeneDx Holdings Corp. Payments for Restructuring
GeneDx Holdings Corp. (WGS) reported Payments for Restructuring of $9.70 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-20.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2025-02-20
- GeneDx Holdings Corp. payments for restructuring for the quarter ending 2023-12-31 was $1.62M.
- GeneDx Holdings Corp. payments for restructuring for the quarter ending 2023-09-30 was $3.33M, a 99.96% decline year-over-year.
- GeneDx Holdings Corp. payments for restructuring for the quarter ending 2023-06-30 was $799.00K.
- GeneDx Holdings Corp. payments for restructuring for the quarter ending 2023-03-31 was $3.95M.
- GeneDx Holdings Corp. payments for restructuring for fiscal 2023 was $9.70M, a 53.33% decline from fiscal 2022.
- GeneDx Holdings Corp. payments for restructuring for fiscal 2022 was $20.79M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month | Payments for Restructuring 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $4.95M derived: sum of 2 quarters · filed 2025-02-20 | $5.75M derived: sum of 3 quarters · filed 2025-02-20 | $9.70M 10-K · filed 2025-02-20 | |
| 2023-09-30 | $3.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $4.13M derived: sum of 2 quarters · filed 2023-11-03 | $8.08M 10-Q · filed 2023-11-03 | -$8.73B derived: sum of 4 quarters · filed 2024-02-23 | |
| 2023-06-30 | $799.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $4.75M 10-Q · filed 2023-08-08 | -$8.73B derived: sum of 3 quarters · filed 2024-02-23 | $19.18M derived: sum of 4 quarters · filed 2024-02-23 | |
| 2023-03-31 | $3.95M 10-Q · filed 2023-05-09 | -$8.73B derived: sum of 2 quarters · filed 2024-02-23 | $18.38M derived: sum of 3 quarters · filed 2024-02-23 | ||
| 2022-12-31 | -$8.74B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $14.43M derived: sum of 2 quarters · filed 2024-02-23 | $20.79M 10-K · filed 2024-02-23 | $19.14M 10-K · filed 2023-03-16 | |
| 2022-09-30 | $8.75B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $8.76B 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $6.36M 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |